share_log

Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Harrington Investments INC

Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Harrington Investments INC

哈灵顿投资公司出售的霍洛奇公司(纳斯达克代码:HOLX)股票
Financial News Live ·  2022/10/03 10:32

Harrington Investments INC reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,704 shares of the medical equipment provider's stock after selling 400 shares during the period. Harrington Investments INC's holdings in Hologic were worth $603,000 at the end of the most recent reporting period.

据哈灵顿投资公司在提交给美国证券交易委员会的最新文件中称,该公司在第二季度将其在纳斯达克公司(Sequoia Capital,Inc.)的股票持仓削减了4.4%。在此期间出售了400股后,该机构投资者持有这家医疗设备提供商的股票8,704股。在最近一个报告期结束时,哈灵顿投资公司在霍洛奇公司持有的股份价值603,000美元。

Several other institutional investors and hedge funds have also made changes to their positions in the company. Integrated Advisors Network LLC increased its position in Hologic by 17.1% in the first quarter. Integrated Advisors Network LLC now owns 3,800 shares of the medical equipment provider's stock worth $292,000 after buying an additional 555 shares during the period. Advisor Group Holdings Inc. increased its position in Hologic by 32.4% in the first quarter. Advisor Group Holdings Inc. now owns 38,475 shares of the medical equipment provider's stock worth $2,721,000 after buying an additional 9,410 shares during the period. McGuire Investment Group LLC increased its position in Hologic by 1.2% in the first quarter. McGuire Investment Group LLC now owns 147,777 shares of the medical equipment provider's stock worth $11,352,000 after buying an additional 1,818 shares during the period. Crossmark Global Holdings Inc. increased its position in Hologic by 56.5% in the first quarter. Crossmark Global Holdings Inc. now owns 43,727 shares of the medical equipment provider's stock worth $3,359,000 after buying an additional 15,780 shares during the period. Finally, CIBC Asset Management Inc increased its position in Hologic by 196.3% in the first quarter. CIBC Asset Management Inc now owns 71,148 shares of the medical equipment provider's stock worth $5,466,000 after buying an additional 47,134 shares during the period. 85.70% of the stock is owned by institutional investors and hedge funds.

其他几家机构投资者和对冲基金也对他们在该公司的头寸进行了调整。第一季度,集成顾问网络有限责任公司将其在霍洛奇的头寸增加了17.1%。集成顾问网络有限责任公司现在拥有这家医疗设备提供商的3800股票,价值29.2万美元,在此期间又购买了555股。Advisor Group Holdings Inc.在第一季度将其在霍洛奇的头寸增加了32.4%。Advisor Group Holdings Inc.现在持有这家医疗设备提供商38,475股股票,价值2,721,000美元,在此期间又购买了9,410股。McGuire Investment Group LLC在第一季度将其在霍洛奇的头寸增加了1.2%。麦奎尔投资集团现在拥有147,777股这家医疗设备提供商的股票,价值11,352,000美元,在此期间又购买了1,818股。今年第一季度,Crossmark Global Holdings Inc.将其在霍洛奇的持仓增加了56.5%。Crossmark Global Holdings Inc.现在持有这家医疗设备提供商43,727股股票,价值3,359,000美元,在此期间又购买了15,780股。最后,加拿大帝国商业银行资产管理公司在第一季度将其在霍洛奇的头寸增加了196.3%。加拿大帝国商业银行资产管理公司(CIBC Asset Management Inc.)目前持有这家医疗设备提供商71,148股票,价值5,466,000美元,在此期间又购买了47,134股票。85.70%的股票由机构投资者和对冲基金持有。

Get
到达
Hologic
荷兰学
alerts:
警报:

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Several research analysts have recently issued reports on HOLX shares. BTIG Research cut Hologic from a "buy" rating to a "neutral" rating in a research note on Monday, July 18th. Bank of America cut Hologic from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $81.00 to $75.00 in a research note on Wednesday, July 20th. Morgan Stanley decreased their price target on Hologic from $72.00 to $70.00 and set an "equal weight" rating for the company in a research note on Thursday, July 28th. Finally, UBS Group started coverage on Hologic in a research note on Wednesday, July 20th. They issued a "neutral" rating and a $73.00 price target for the company. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Hologic has a consensus rating of "Hold" and an average target price of $76.71.

几位研究分析师最近发布了关于HOLX股票的报告。BTIG Research在7月18日星期一的一份研究报告中将霍洛奇的评级从“买入”下调至“中性”。美国银行在7月20日星期三的一份研究报告中,将霍洛奇的评级从买入下调至中性,并将该股的目标价从81.00美元下调至75.00美元。摩根士丹利在7月28日周四的一份研究报告中将他们对霍洛奇的目标价从72.00美元下调至70.00美元,并为该公司设定了“同等权重”的评级。最后,瑞银集团在7月20日星期三的一份研究报告中开始对霍洛奇进行报道。他们对该公司的评级为中性,目标价为73.00美元。七位分析师对该股的评级为持有,四位分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,霍洛奇的普遍评级为持有,平均目标价为76.71美元。

Hologic Price Performance

高性价比

HOLX stock traded up $1.40 during trading hours on Monday, hitting $65.92. 2,996 shares of the stock traded hands, compared to its average volume of 1,760,696. The stock has a 50-day simple moving average of $68.85 and a 200 day simple moving average of $72.05. Hologic, Inc. has a one year low of $61.57 and a one year high of $80.49. The company has a market cap of $16.46 billion, a P/E ratio of 10.88, a P/E/G ratio of 0.73 and a beta of 1.02. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57.
周一交易时段,HOLX股价上涨1.40美元,触及65.92美元。该股有2,996股易手,而平均成交量为1,760,696股。该股的50日简单移动均线切入位为68.85美元,200日简单移动均线切入位为72.05美元。霍洛奇公司的一年低点为61.57美元,一年高位为80.49美元。该公司市值164.6亿美元,市盈率10.88倍,市盈率0.73倍,贝塔系数1.02。该公司的流动比率为3.91,速动比率为3.32,债务权益比率为0.57。

Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $896.71 million. During the same quarter last year, the business posted $1.33 earnings per share. The company's quarterly revenue was down 14.2% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 5.82 earnings per share for the current year.

霍洛奇公司(纳斯达克代码:HOLX-GET Rating)上一次公布财报是在7月27日星期三。这家医疗设备提供商公布本季度每股收益为0.95美元,比普遍预期的0.69美元高出0.26美元。霍洛奇的股本回报率为37.48%,净利润率为28.93%。该业务当季营收为10亿美元,高于分析师预期的8.9671亿美元。去年同一季度,该公司公布的每股收益为1.33美元。该公司季度营收同比下降14.2%。股票分析师预测,霍洛奇公司本年度每股收益将达到5.82美元。

Hologic Profile

霍洛奇剖面

(Get Rating)

(获取评级)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

霍洛奇公司在美国、欧洲、亚太地区和国际上开发、制造和供应诊断产品、医学成像系统和外科产品,通过早期发现和治疗来保护妇女的健康。它通过四个部分运作:诊断、乳房健康、妇科外科和骨骼健康。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Hologic (HOLX)
  • Near-Term Headwinds Send Nike To The Bargain Basement
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • Is the Bond Market Signaling a Market Bottom?
  • 免费获取StockNews.com关于霍洛奇的研究报告(HOLX)
  • 近期的逆风将耐克送到了廉价地下室
  • 阿彻·丹尼尔斯·米德兰:49年增长的红利英雄
  • 全自动拖拉机会让迪尔成为农业领域的特斯拉吗?
  • 麦格纳国际是您的汽车和电动汽车一站式库存
  • 债券市场是否发出了市场触底的信号?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).

想看看其他对冲基金持有HOLX吗?访问HoldingsChannel.com获取霍洛奇公司(纳斯达克代码:HOLX-GET Rating)的最新13F备案文件和内幕交易信息。

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

接受《荷兰语日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对霍洛奇及相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发